Biopharma
R&D Workflows.
Revolutionized.
Top biopharma, biotech, and CRDMO organizations trust Genedata to digitalize, automate, and connect workflows across discovery, development, and manufacturing. By unifying data, advanced analytics, and AI in a single platform, Genedata eliminates manual data management, streamlines processes, and turns complex processes into insight-driven decisions.
Our Customers
Explore Key Areas
Connect processes and teams, unlock your data and insights, and accelerate R&D.
- All Assays & Analytics
- Biotherapeutics Discovery
- Bioprocess Development
- Chromatography Workflows
- Mass Spectrometry Workflows
- NGS-Based Workflows
- Precision Medicine
- Centralized, structured assay data with full context, traceability, and audit trails.
- Automated end-to-end workflows from instrument readout to QC, visualization, and reports.
- Support for complex, high-throughput and multiplexed assays across discovery and development.
- Integrated workflows to design, screen, and optimize biologics, from early hits to lead candidates.
- Built-in support for next-gen antibodies and ADCs, with shared registration and analytics across modalities.
- End-to-end traceability linking sequence, assays, and developability data to accelerate candidate selection and reduce risk.
- Integrated workflows to connect cell line development, upstream and downstream processing, formulation, and analytical development in one environment.
- End-to-end data capture and compliant analytics to support Quality by Design, digital twins, and efficient tech transfer to manufacturing.
- Automated, harmonized processing and reporting of all chromatography and CE data in a single system.
- End-to-end workflows for purification development, CQA monitoring, and developability assessments, reducing analysis time and errors.
- Streamlined MS data pipelines for in-depth molecular characterization, process monitoring, and multi-attribute methods.
- GxP-ready, configurable workflows that support QC, product quality assessment, and regulatory expectations.
- NGS workflows covering discovery, bioprocess development, genome editing, biosafety testing, and QC.
- Scalable, automated pipelines that integrate with upstream and downstream analytics to support omics-driven process optimization and translational research.
- Integrated management and analysis of high-dimensional translational and clinical datasets.
- Identification and validation of novel biomarkers, therapeutic indications, and response signatures.
- Tools to design data-driven clinical trials and link R&D insights to real-world data.
All Modalities
Genedata supports all therapeutic modalities in one integrated platform, eliminating siloed point solutions and providing a single source of truth for all data and processes.
- Biotherapeutics and Next-Gen Antibodies
- Antibody-Drug Conjugates
- Cell Therapies
- Gene Therapies
- CRISPR Therapies
- RNA Therapies
- Vaccines
- Small Molecules
- Support for monoclonal antibodies, bispecifics, multispecifics, and other complex biologics throughout discovery and optimization.
- Integrated workflows for library design, screening, hit triage, engineering, and developability assessment.
- Registration, tracking, and analytics for large molecule entities with complete molecular history.
- Dedicated workflows for managing conjugation, payload-linker design, and complex characterization data.
- Integrated chromatography and MS analytics to monitor DAR, stability, and critical quality attributes.
- Purpose-built workflows for designing, engineering, and developing cell therapy products with full traceability across vectors, cells, and processes.
- Integrated analytics to connect NGS, flow cytometry, imaging, and functional assays for in-depth product characterization and performance assessment.
- Dedicated workflows for managing vector design, genome integration strategies, and complex characterization data throughout gene therapy development.
- Seamless integration with NGS and other analytical technologies for assessing integration sites, off-target effects, and long-term product quality.
- Specialized workflows to orchestrate CRISPR target design, editing strategies, and verification within a single, controlled environment.
- Automated analytics that combine NGS, functional readouts, and QC data for robust evaluation of on-target activity and off-target risk.
- Integrated workflows to support RNA design, production, formulation, and analytical characterization for mRNA and other RNA modalities.
- Consolidated assay and process data to optimize RNA quality, stability, and performance across discovery, development, and CMC.
- Digitalized workflows for nucleic acid, viral vector, and protein-based vaccine programs from early discovery through development.
- Unified analytical data streams to monitor immunogenicity, safety, and critical quality attributes for diverse vaccine candidates.
- High-throughput screening and profiling workflows for small molecules, integrated with biophysical and functional assays.
- Standardized analytics that enable the rapid progression of high-value candidates and portfolio-level insights.